Stock Evaluator: Insulet Corporation (PODD)

Insulet Corporation PODD

$141.10 2.33 1.68%
October 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,618,286
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics PODD Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $9,785.9 $382.9 78%
Shares Out (Mil) 69.4 40.9 55%
Institutional Ownership 99.7% 83.6% 92%
Float (Mil) 69.1 35.5 54%
Beta 1.08 0.86 65%
Avg Daily Volume (000s) 1,538 301 77%
Price Change
(52-week)
(54.8%) 61.8% 18%
Growth PODD Industry
Median
Percentile
(All Stocks)
Sales (5yr) 24.5% 11.8% 86%
Net Income (5yr) 105.2% (5.5%) 99%
EPS (5yr) 103.4% 10.6% 99
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (18.2%) (15.5%) 38%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 23 24 24
Current EPS $1.588 $6.507 $7.722
Month Ago EPS $1.587 $6.503 $7.711
# Rev Up 1 1 1
# Rev Down 1 0 0
Three Months Ago EPS $1.633 $6.478 $8.054
Year/Year Chg 15.9% 87.0% 164.7%
Financials PODD Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $3,053 $141 67%
Net Income (TTM) (Mil) $375 ($9) 75%
EPS (TTM) $5.361 ($0.400) 87%
Operating Cash Flow (TTM) (Mil) $511 ($2) 72%
Net Cash Flow (TTM) (Mil) ($587) $1 5%
Long-Term Debt (Q1) (Mil) $930 $27 65%
Enterprise Value (Q1) (Mil) $10,231 $418 74%
Valuation PODD Industry
Median
Percentile
(All Stocks)
P/B 6.88 2.50 86%
P/E 26.6 25.8 66%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.3 1.4 11%
Ratios PODD Industry
Median
Percentile
(All Stocks)
Gross Margin 71.1% 58.7% 82%
Net Margin 12.3% (6.9%) 68%
ROA 11.3% (12.2%) 89%
ROE 26.0% (10.7%) 85%
Liabilities to Assets 55.1% 47.2% 48%
F-Score 9 4 98%

Insulet Corporation did not pass any screens on 10/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors